Skip to main content
. Author manuscript; available in PMC: 2016 Feb 2.
Published in final edited form as: Diabetologia. 2013 Apr 19;56(7):1661–1669. doi: 10.1007/s00125-013-2907-z

Fig. 7.

Fig. 7

Inhibition of diabetic-stimuli-induced FKN/CX3CR1 and FKN-induced ECM secretion in MMCs treated with TGF-β-neutralising antibody (FKN at 50 ng/ml). Fkn (a) and Cx3cr1 (b) mRNA levels were measured in MMCs exposed to HG (30 mmol/l d-glucose) and OA (100 µmol/l OA) with or without a TGF-β-neutralising antibody. ECM markers such as Fn (c) and Col4α1 (d) mRNA expression were assessed in MMCs incubated with a TGF-β-neutralising antibody before stimulation with FKN. Data are mean±SE of four experiments. *p<0.05 vs control; †p<0.05 vs HG, OA or FKN. Black bars, treated in 5 µg/ml IgG; white bars, treated in 5 µg/ml TGF-β-neutralising antibody. Con, control